Stock Events

Stock Events

Oncoinvent ASA.

€4.37

67

-€0.19-4.17% Today

Statistics

Day High

4.37

Day Low

4.37

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

170.81M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

19FebExpected

Q2 2024

Q3 2024

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q4 2025

-0.13

-0.11

-0.08

-0.06

Expected EPS

N/A

Actual EPS

N/A

Financials

-16,698.77%Profit Margin

Unprofitable

2019

2020

2021

2022

2023

2024

144,070.89Revenue

-24.06MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7BG.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which competes with BerGenBio's cancer-focused pipeline.

Amgen Inc. is a biotechnology company that develops and produces medicines in areas including oncology/hematology, competing directly with BerGenBio's cancer treatment developments.

Gilead Sciences

Gilead Sciences, Inc. is involved in the research, development, and commercialization of drugs in areas such as oncology, directly competing with BerGenBio's therapeutic areas.

Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals across various areas, including cancer, making it a competitor to BerGenBio.

Bristol-Myers Squibb

Bristol-Myers Squibb Company offers biopharmaceutical products, including those for cancer treatment, competing with BerGenBio's oncology focus.

Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, which competes with BerGenBio's product range.

Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products including oncology treatments, competing with BerGenBio.

Roche Holding AG focuses on pharmaceuticals and diagnostics in oncology, among other areas, directly competing with BerGenBio's cancer therapies.

AstraZeneca PLC is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with BerGenBio.

Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of a range of pharmaceutical products, including those for cancer, making it a competitor to BerGenBio.

About

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.

Show more...

CEO

Employees

45

Country

Other

ISIN

NO0013711713

WKN

000A41YN5

Listings

0 Comments

Share your thoughts

FAQ

What is Oncoinvent ASA. stock price today?▼

The current price of 7BG.F is €4.37 EUR — it has decreased by -4.17% in the past 24 hours. Watch Oncoinvent ASA. stock price performance more closely on the chart.

What is Oncoinvent ASA. stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncoinvent ASA. stocks are traded under the ticker 7BG.F.

What is Oncoinvent ASA. market cap?▼

Today Oncoinvent ASA. has the market capitalization of 170.81M

What is Oncoinvent ASA. revenue for the last year?▼

Oncoinvent ASA. revenue for the last year amounts to 144,070.89 EUR.

What is Oncoinvent ASA. net income for the last year?▼

7BG.F net income for the last year is -24.06M EUR.

How many employees does Oncoinvent ASA. have?▼

As of April 21, 2026, the company has 45 employees.

In which sector is Oncoinvent ASA. located?▼

Oncoinvent ASA. operates in the Health & Wellness sector.

When did Oncoinvent ASA. complete a stock split?▼

The last stock split for Oncoinvent ASA. was on January 19, 2026 with a ratio of 1:100.